Annual EBIT
-$10.15 M
-$59.07 M-120.75%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual earnings before interest & taxes is currently -$10.15 million, with the most recent change of -$59.07 million (-120.75%) on 31 December 2023. During the last 3 years, it has risen by +$22.65 million (+69.05%).ACRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$4.51 M
-$3.09 M-218.50%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly earnings before interest & taxes is currently -$4.51 million, with the most recent change of -$3.09 million (-218.50%) on 31 December 2023.ACRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$9.71 M
+$2.79 M+22.29%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM earnings before interest & taxes is currently -$9.71 million, with the most recent change of +$2.79 million (+22.29%) on 31 December 2023.ACRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +69.0% | +39.5% | +70.4% |
| 5 y5 years | +80.0% | +66.8% | +80.6% |
ACRX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -120.8% | -106.0% | -115.9% |
AcelRx Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$10.15 M(-120.8%) | -$4.51 M(+218.5%) | -$9.71 M(-22.3%) |
| Sept 2023 | - | -$1.42 M(-64.3%) | -$12.50 M(-28.9%) |
| June 2023 | - | -$3.97 M(-2268.9%) | -$17.57 M(-128.8%) |
| Mar 2023 | - | $183.00 K(-102.5%) | $61.01 M(+7.8%) |
| Dec 2022 | $48.92 M(-249.1%) | -$7.30 M(+12.4%) | $56.60 M(+0.3%) |
| Sept 2022 | - | -$6.49 M(-108.7%) | $56.44 M(+2.4%) |
| June 2022 | - | $74.61 M(-1865.9%) | $55.10 M(-291.8%) |
| Mar 2022 | - | -$4.22 M(-43.3%) | -$28.73 M(-12.4%) |
| Dec 2021 | -$32.80 M(-11.5%) | -$7.45 M(-4.9%) | -$32.79 M(-2.1%) |
| Sept 2021 | - | -$7.84 M(-15.0%) | -$33.50 M(-0.8%) |
| June 2021 | - | -$9.22 M(+11.3%) | -$33.77 M(+11.5%) |
| Mar 2021 | - | -$8.28 M(+1.5%) | -$30.28 M(-18.2%) |
| Dec 2020 | -$37.07 M(-26.9%) | -$8.16 M(+0.7%) | -$37.01 M(-12.8%) |
| Sept 2020 | - | -$8.11 M(+41.5%) | -$42.43 M(-8.2%) |
| June 2020 | - | -$5.73 M(-61.8%) | -$46.23 M(-13.4%) |
| Mar 2020 | - | -$15.01 M(+10.4%) | -$53.41 M(+6.6%) |
| Dec 2019 | -$50.70 M(+46.6%) | -$13.59 M(+14.2%) | -$50.09 M(+6.6%) |
| Sept 2019 | - | -$11.90 M(-7.8%) | -$46.98 M(+6.5%) |
| June 2019 | - | -$12.90 M(+10.4%) | -$44.09 M(+15.6%) |
| Mar 2019 | - | -$11.69 M(+11.5%) | -$38.15 M(+10.3%) |
| Dec 2018 | -$34.59 M(-9.4%) | -$10.48 M(+16.3%) | -$34.59 M(+48.7%) |
| Sept 2018 | - | -$9.02 M(+29.6%) | -$23.25 M(-11.7%) |
| June 2018 | - | -$6.96 M(-14.4%) | -$26.33 M(-16.5%) |
| Mar 2018 | - | -$8.13 M(-1053.5%) | -$31.53 M(-11.5%) |
| Dec 2017 | -$38.17 M(+23.0%) | $853.00 K(-107.1%) | -$35.61 M(-1.3%) |
| Sept 2017 | - | -$12.09 M(-0.5%) | -$36.07 M(+3.9%) |
| June 2017 | - | -$12.15 M(-0.5%) | -$34.71 M(+5.3%) |
| Mar 2017 | - | -$12.22 M(-3147.1%) | -$32.96 M(+6.2%) |
| Dec 2016 | -$31.04 M | $401.00 K(-103.7%) | -$31.04 M(-20.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$10.74 M(+3.2%) | -$38.89 M(+80.1%) |
| June 2016 | - | -$10.40 M(+1.0%) | -$21.60 M(+11.8%) |
| Mar 2016 | - | -$10.30 M(+38.3%) | -$19.31 M(+5.9%) |
| Dec 2015 | -$18.23 M(-40.6%) | -$7.45 M(-213.7%) | -$18.23 M(-23.3%) |
| Sept 2015 | - | $6.55 M(-180.7%) | -$23.78 M(-17.6%) |
| June 2015 | - | -$8.12 M(-11.9%) | -$28.85 M(-6.3%) |
| Mar 2015 | - | -$9.22 M(-29.1%) | -$30.77 M(+0.2%) |
| Dec 2014 | -$30.71 M(+360.7%) | -$13.00 M(-974.0%) | -$30.71 M(-296.8%) |
| Sept 2014 | - | $1.49 M(-114.8%) | $15.61 M(+348.3%) |
| June 2014 | - | -$10.04 M(+9.7%) | $3.48 M(-198.9%) |
| Mar 2014 | - | -$9.16 M(-127.5%) | -$3.52 M(-47.2%) |
| Dec 2013 | -$6.67 M(-77.6%) | $33.32 M(-413.2%) | -$6.67 M(-86.3%) |
| Sept 2013 | - | -$10.64 M(-37.6%) | -$48.63 M(+5.7%) |
| June 2013 | - | -$17.04 M(+38.5%) | -$46.00 M(+29.4%) |
| Mar 2013 | - | -$12.31 M(+42.5%) | -$35.55 M(+19.6%) |
| Dec 2012 | -$29.71 M(+67.0%) | -$8.64 M(+7.8%) | -$29.71 M(+17.4%) |
| Sept 2012 | - | -$8.01 M(+21.4%) | -$25.31 M(+11.5%) |
| June 2012 | - | -$6.60 M(+1.9%) | -$22.70 M(+9.5%) |
| Mar 2012 | - | -$6.47 M(+52.9%) | -$20.73 M(+16.5%) |
| Dec 2011 | -$17.79 M(+37.4%) | -$4.23 M(-21.7%) | -$17.79 M(+3.7%) |
| Sept 2011 | - | -$5.41 M(+17.0%) | -$17.16 M(+19.5%) |
| June 2011 | - | -$4.62 M(+30.7%) | -$14.36 M(+10.0%) |
| Mar 2011 | - | -$3.54 M(-1.9%) | -$13.05 M(+0.8%) |
| Dec 2010 | -$12.95 M(-32.0%) | -$3.60 M(+38.4%) | -$12.95 M(+0.2%) |
| Sept 2010 | - | -$2.60 M(-21.3%) | -$12.92 M(+25.3%) |
| June 2010 | - | -$3.31 M(-3.6%) | -$10.32 M(+47.2%) |
| Mar 2010 | - | -$3.43 M(-3.9%) | -$7.01 M(+96.1%) |
| Dec 2009 | -$19.03 M(-6.1%) | -$3.57 M | -$3.57 M |
| Dec 2008 | -$20.26 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ACRX is -$10.15 M
What is the all time high annual EBIT for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual earnings before interest & taxes is $48.92 M
What is AcelRx Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ACRX is -$4.51 M
What is the all time high quarterly EBIT for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly earnings before interest & taxes is $74.61 M
What is AcelRx Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ACRX is -$9.71 M
What is the all time high TTM EBIT for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM earnings before interest & taxes is $61.01 M